bemnifosbuvir + ruzasvir + biktarvy

Bemnifosbuvir + ruzasvir + biktarvy is a combination of direct acting antivirals and an antiretroviral regimen, currently being studied for potential drug-drug interactions. Bemnifosbuvir is an oral purine nucleotide prodrug that inhibits the hepatitis C virus (HCV) nonstructural protein 5B (NS5B), an RNA-dependent RNA polymerase essential for viral replication. Ruzasvir is a potent, selective inhibitor of HCV nonstructural protein 5A (NS5A), another key component in the viral replication complex. Both agents are pan-genotypic and have demonstrated synergistic antiviral activity against HCV with favorable safety profiles and low risk of drug-drug interactions[3][6][8]. Biktarvy is a fixed-dose combination tablet containing bictegravir, emtricitabine, and tenofovir alafenamide; it acts as a complete treatment for HIV‑1 infection by inhibiting HIV integrase and reverse transcriptase enzymes to prevent viral replication[2]. The combination of bemnifosbuvir plus ruzasvir has shown high efficacy in phase 2 trials for HCV with SVR12 rates above 95%[7][8], while Biktarvy is approved for HIV‑1 treatment.

Brand names

Biktarvy (for bictegravir + emtricitabine + tenofovir alafenamide)

Other names

bictegravir/emtricitabine/tenofovir alafenamide (for Biktarvy)bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate (for Biktarvy)